MONROVIA, Calif. --(BUSINESS WIRE)--Dec. 20, 2019-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Dagmar
MONROVIA, Calif. --(BUSINESS WIRE)--Sep. 10, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Celia Eckert as
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 9, 2024-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 19, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Barbara J.
MONROVIA, Calif. --(BUSINESS WIRE)--Dec. 18, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Allen Yang ,
MONROVIA, Calif. , March 19, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of A.
- Positive trend in primary endpoint; proportion of efficacy-evaluable patients who did not experience loss of improvement (LOI) by Day 225 did not meet statistical significance (XmAb®5871 42% vs. placebo 28.6%, p = 0.18) - Met secondary endpoint of time to LOI; risk of LOI reduced by 47% for
MONROVIA, Calif. --(BUSINESS WIRE)--Jun. 27, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that Paul Foster , M.D., senior
- Novartis to receive ex-U.S. rights to XmAb14045 and XmAb13676- Xencor retains all U.S. rights to XmAb14045 and XmAb13676- Collaboration also includes XmAb Bispecific Technology for 4 Novartis targets and access to Xencor Fc Technologies